Alnylam Pharmaceuticals
ALNY
#536
Rank
$43.59 B
Marketcap
$328.73
Share price
-0.65%
Change (1 day)
28.53%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2025 (TTM): $0.57 Billion USD

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are $3.71 Billion USD. , an increase over its 2024 earnings that were of -$0.24 Billion USD. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2025

Annual earnings

Year Earnings Change
2025 $0.57 B-344.47%
2024 -$0.24 Billion-24.59%
2023 -$0.32 Billion-67.84%
2022 -$0.98 Billion36.93%
2021 -$0.71 Billion-8.04%
2020 -$0.78 Billion-15.66%
2019 -$0.92 Billion12.23%
2018 -$0.82 Billion62.91%
2017 -$0.51 Billion17.78%
2016 -$0.43 Billion43.44%
2015 -$0.3 Billion60.69%
2014 -$0.19 Billion98.2%
2013 -$92.95 Million
2011 -$54.82 Million27.48%
2010 -$43.01 Million-10.92%
2009 -$48.28 Million95.77%
2008 -$24.66 Million
2006 -$39.51 Million-9.13%
2005 -$43.48 Million34.74%
2004 -$32.27 Million36.79%
2003 -$23.59 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
$16.35 B 2,739.98%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
$7.69 B 1,237.20%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
$5.23 B 808.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-$0.26 Billion-143.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-$47.43 Million-108.24%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-$0.16 Billion-127.70%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
$2.15 B 273.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
$0.34 B-40.06%๐Ÿ‡บ๐Ÿ‡ธ USA